Anebulo Pharmaceuticals, Inc. ( (ANEB) ) has released its Q2 earnings. Here is a breakdown of the information Anebulo Pharmaceuticals, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, particularly for pediatric patients. In its recent financial report, Anebulo announced key developments and financial outcomes for the second quarter of fiscal year 2025. The company highlighted a meeting with the FDA to discuss advancing its intravenous formulation of selonabant for treating pediatric cannabis toxicity, a significant step in addressing this unmet medical need. Financially, Anebulo reported operating expenses of $2.6 million and a net loss of $2.5 million, showing slight improvements compared to the previous year. Anebulo also secured a $15 million private placement, strengthening its cash position to support ongoing development efforts. Looking ahead, Anebulo remains focused on its strategic plan to advance selonabant, with the potential for a faster timeline to approval for pediatric use, reflecting management’s optimism about its future prospects.